Logo for Enlivex Therapeutics Ltd

Enlivex Therapeutics Investor Relations Material

Latest events

Logo for Enlivex Therapeutics

Q3 2024

28 Nov, 2024
Logo for Enlivex Therapeutics

Q2 2024

29 Aug, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies

Latest reports from Enlivex Therapeutics Ltd

Access all reports
Enlivex Therapeutics Ltd is an Israel-based clinical-stage biopharmaceutical company focused on developing allogeneic cell therapies for life-threatening immune-related diseases. The company’s lead investigational product is designed to modulate the immune system to restore immune balance in conditions such as sepsis, solid tumors, and other inflammatory disorders. Enlivex conducts clinical trials and research to advance its immunotherapy platform. The company is headquartered in Nes Ziona, Israel, and its shares are listed on the NASDAQ.